Effects of Bosutinib on cerebral ischemia/reperfusion injury in rats

doi:10.12047/j.cjap.6327.2022.146

Abstract

Abstract: Objective: To investigate the effects of bosutinib on the early stage of cerebral ischemia-reperfusion injury in rats. Methods: Forty Sprague-Dawley rats were randomly divided into four groups (random number method), 10 rats in each group; sham group (control group): only neck vessels were isolated without other treatments; MCAO (model group): the rat brain ischemia/reperfusion injury model was made by a modified wire bolus method,ischemia for 2 h followed by reperfusion for 24 h; DMSO group (solvent group): DMSO ( 0.752 ml/kg) was injected into the tail vein one day before the experiment, brain ischemia 2 h reperfusion for 24 h; Bosutinib group (intervention group): one day before the experiment, the tail vein was injected with Bosutinib (4 mg/kg), brain ischemia 2 h reperfusion for 24 h. After 24 h of ischemia reperfusion, neurological function score was performed; brain infarct area was calculated after staining with TTC; SIK2 was detected by Western blot; the contents of TNF-α and IL-6 in brain tissue were detected by ELISA. Results: Compared with the sham group, the neurological function scores, the infarct volume percentages and the levels of inflammatory factors IL-6 and TNF-α of the MCAO and DMSO groups were increased significantly (P＜0.05 or P＜0.01). Compared with the MCAO and DMSO groups, the above mentioned indexes of the bosutinib group were all decreased significantly (P＜0.05 or P＜ 0.01). Compared with sham group, the expression levels of SIK2 protein in MCAO and DMSO groups had no significant changes(P＞ 0.05); compared with the MCAO and DMSO group, the expression level of SIK2 protein in the bosutinib group was decreased significantly (P＜0.05). Conclusion: Bosutinib reduces cerebral ischemia-reperfusion-induced injury, and its possible mechanism is related to the decreased expression of SIK2 protein and inflammatory factors.

Key words: Bosutinib, cerebral ischemia-reperfusion injury, SIK2, inflammation

CLC Number:

R743.3

ZHANG Yi, WU Chao, ZHANG Qi, KONG Yyu, BIAN Xiao-qian, WANG Ying, LI Shu. Effects of Bosutinib on cerebral ischemia/reperfusion injury in rats[J]. CJAP, 2022, 38(6): 803-806.

References

[1] Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention[J]. Circ Res, 2017, 120(3): 472-495.
[2] Przykaza L. Understanding the connection between common stroke comorbidities, their associated inflammation, and the course of the cerebral ischemia/reperfusion cascade[J]. Front Immunol, 2021, 12: 1-17.
[3] Gallo EF, Iadecola C. Balancing life and death in the ischemic brain: SIK and TORC weigh in[J]. Neuron, 2011, 69(1): 3-6.
[4] Ma L, Manaenko A, Ou YB, et al. Bosutinib attenuates inflammation via inhibiting salt-inducible kinases in experimental model of intracerebral hemorrhage on mice[J]. Stroke, 2017, 48(11): 3108-3116.
[5] Darling NJ, Cohen P. Nuts and bolts of the salt-inducible kinases (SIKs)[J]. Biochem J, 2021, 478(7): 1377-1397.
[6] Ozanne J, Prescott AR, Clark K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases[J]. Biochem J, 2015, 465(2): 271-279.
[7] Sundberg TB, Choi HG, Song JH, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells[J]. Proc Natl Acad Sci U S A, 2014, 111(34): 12468-12473.
[8] Mo Y, Sun YY, Liu KY. Autophagy and inflammation in ischemic stroke[J]. Neural Regen Res, 2020, 15(8): 1388-1396.
[9] Huang Y, Chen S, Luo Y, et al. Crosstalk between inflammation and the BBB in stroke[J]. Curr Neuropharmacol, 2020, 18(12): 1227-1236.
[10] Levard D, Buendia I, Lanquetin A, et al. Filling the gaps on stroke research: Focus on inflammation and immunity[J]. Brain Behav Immun, 2021, 91: 649-667.
[11] Shi K, Tian DC, Li ZG, et al. Global brain inflammation in stroke[J]. Lancet Neurol, 2019, 18(11): 1058-1066.
[12] Zhang B, Gao M, Shen J, et al. Inhaled methane protects rats against neurological dysfunction induced by cerebral ischemia and reperfusion injury: PI3K/Akt/HO-1 pathway involved[J]. Arch Med Res, 2017, 48(6): 520-525.
[13] 孙科, 罗招亮, 胡琛, 等. 小檗碱对大鼠脑缺血/再灌注损伤的保护作用及免疫机制[J]. 中国应用生理学杂志, 2020, 36(6): 656-661.
[14] 吴超. SIK-2对脑缺血再灌注损伤的影响及机制研究: 皖南医学院, 2019.
[15] Sasaki T, Takemori H, Yagita Y, et al. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB[J]. Neuron, 2011, 69(1): 106-119.
[16] Chen B, Liao WQ, Xu N, et al. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action[J]. Brain Res, 2009, 1273: 129-137.
[17] Li Q, Cao Y, Dang C, et al. Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke[J]. EMBO Mol Med, 2020, 12(4): e11002.
[18] Zhang Z, Qin P, Deng Y, et al. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation[J]. J Neuroinflamm, 2018, 15(1): 206.
[19] Mo ZT, Zheng J, Liao YL. Icariin inhibits the expression of IL-1β, IL-6 and TNF-α induced by OGD/R through the IRE1/XBP1s pathway in microglia[J]. Pharm Biol, 2021, 59(1): 1473-1479.
[20] 张莉莉, 王景周, 周华东, 等. 肿瘤坏死因子-α在大鼠脑缺血再灌注损伤中的作用机制[J]. 中华老年医学杂志, 2003, 22(2): 102-104.
[21] 李俊杰, 蒋海燕, 邵建林. 脑缺血-再灌注损伤大鼠脑组织中TNF-α,IL-6和IL-1β的表达[J]. 昆明医科大学学报, 2016, 37(9): 31-35.
[22] Chen AQ, Fang Z, Chen XL, et al. Microglia-derived TNF-α mediates endothelial necroptosis aggravating blood brain-barrier disruption after ischemic stroke[J]. Cell Death Dis, 2019, 10(7): 487.
[23] Lin SY, Wang YY, Chang CY, et al. TNF-α receptor inhibitor alleviates metabolic and inflammatory changes in a rat model of ischemic stroke[J]. Antioxidants (Basel), 2021, 10(6): 851.
[24] 常红恩, 郑娜, 安红伟, 等. 通窍活血汤对大鼠脑缺血再灌注损伤后血清中TNF-α及IL-6水平的影响[J]. 成都中医药大学学报, 2018, 41(3): 18-20,103.
[25] Zhu T, Meng XB, Dong DX, et al. Xuesaitong injection (lyophilized) combined with aspirin and clopidogrel protect against focal cerebral ischemic/reperfusion injury in rats by suppressing oxidative stress and inflammation and regulating the NOX2/IL-6/STAT3 pathway[J]. Ann Palliat Med, 2021, 10(2): 1650-1667.